SELLAS Life Sciences (SLS) Depreciation & Amortization (CF) (2010 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Depreciation & Amortization (CF) of $25000.0 for Q3 2017, down 16.67% year-over-year from $30000.0 in Q3 2016, and little changed quarter-over-quarter from $25000.0 in Q2 2017.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Depreciation & Amortization (CF) (2010 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $25000.0 the latest figure, recorded in Q3 2017.
- In Q3 2017, Depreciation & Amortization (CF) fell 16.67% year-over-year to $25000.0; the TTM figure through Jun 2018 stood at $25000.0 (up 327.27% YoY), while the FY2016 annual figure was $3000.0, down 97.2% from the prior year.
- Depreciation & Amortization (CF) steadied at $25000.0 in Q3 2017 per SLS's latest filing, from $25000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $232000.0 in Q1 2014 and bottomed at -$254000.0 in Q4 2014.
- Historically, Depreciation & Amortization (CF) has averaged $29368.4 across 5 years, with a median of $30000.0 in 2016.
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 11500.0% in 2014 and fell as far as 315.25% in 2014.
- SELLAS Life Sciences' Depreciation & Amortization (CF) stood at $118000.0 in 2013, then tumbled by 315.25% to -$254000.0 in 2014, then grew by 22.44% to -$197000.0 in 2015, then jumped by 53.3% to -$92000.0 in 2016, then soared by 127.17% to $25000.0 in 2017.
- Business Quant data shows SLS's Depreciation & Amortization (CF) at $25000.0 in Q3 2017, $25000.0 in Q2 2017, and $26000.0 in Q1 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 25,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Dec 31, 2016 | -92,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Jun 30, 2016 | 59,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | -197,000.00 |
| Sep 30, 2015 | 123,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Mar 31, 2015 | 98,000.00 |
| Dec 31, 2014 | -254,000.00 |
| Sep 30, 2014 | -121,000.00 |
| Jun 30, 2014 | 229,000.00 |
| Mar 31, 2014 | 232,000.00 |
| Dec 31, 2013 | 118,000.00 |
| Sep 30, 2013 | 127,000.00 |
| Jun 30, 2013 | 39,000.00 |
| Mar 31, 2013 | 2,000.00 |
| Dec 31, 2012 | 2,000.00 |